Mission Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference
CAMBRIDGE, UK – 6th March 2019 –Mission Therapeutics, a drug discovery and development company focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs), announced today that Dr Anker Lundemose, CEO, will present a company overview at the Cowen and Company 39th Annual Healthcare Conference, in Boston, Massachusetts.
The presentation will take place on Tuesday 12th March at 8.00 am ET.
ENDS
FOR MORE INFORMATION:
| Mission Therapeutics Ltd Anker Lundemose MD PhD Chief Executive Officer Tel: +44 (0) 1223 607340 |
Instinctif Partners Melanie Toyne-Sewell / Eileen Paul Tel: +44 (0) 20 7457 2020 missiontherapeutics@instinctif.com |
NOTES TO EDITORS:
About Mission Therapeutics
Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.
In November 2018, Mission Therapeutics and AbbVie entered into a collaboration in the research and preclinical development of specified DUB inhibitors for the treatment of Alzheimer’s Disease and Parkinson’s Disease. Mission has strong links with key academic and research centers, including Prof. Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company is managed by a team with broad international, commercial and clinical-science experience.
In February 2016, the Company completed a £60m financing that was led by Imperial Innovations (now part of IP Group) and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.
